ArticleJTO clinical and research reports2026
Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010-2023): A Meta-Analysis.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: NSCLC, largely linked to smoking, remains a global health challenge with poor prognosis despite therapeutic advances. Understanding how smoking status affects treatment response is essential for optimizing therapies, yet comprehensive analyses are lacking. Methods: This study evaluates outcome differences by smoking status, assesses smoking rates in trials leading to Food and Drug Administration approval for NSCLC, and estimates overall outcome disparities between smoking status by treatment type. Trials supporting drug approvals for NSCLC in adults between January 2010 and December 2023 were identified from Food and Drug Administration archives. Non-comparative studies, biosimilar studies, and those without a time-to-event end point were excluded. Outcome data based on smoking status subgroups were collected, focusing on progression-free survival (PFS), overall survival (OS), and disease-free or event-free survival for pooled analyses. A trial-level pairwise comparison and random effects meta-analysis assessed outcome differences by smoking status (current/former versus never), with Results: The final cohort comprised 33 trials including 19,660 patients, 74% of whom were smokers, compared with an estimated 87% from U.S. NSCLC population data. No effect modification from smoking status was found across all treatment types. However, differences emerged evaluating specific treatment subtypes: small molecule therapies favored nonsmokers in PFS (n = 11, hazard ratio 1.22, 95% confidence interval 1.03-1.45, Conclusion: Our analysis supports smokers' improved OS from immunotherapy in NSCLC, contrasting with nonsmokers' improved PFS with small molecule therapies, possibly due to differences in tumor mutations and immune microenvironment induced by smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.